Artificial Intelligence in Drug Discovery

Artificial intelligence is being integrated across target identification, molecular design, virtual screening, biomarker discovery, preclinical assessment, and clinical development. Its value lies in processing heterogeneous biological and chemical data, prioritizing experiments, and supporting more reproducible decision-making. Adoption remains dependent on data quality, validation, laboratory integration, regulatory clarity, and specialist talent.

The landscape is shifting from standalone computational tools toward connected workflows that link electronic health records, omics, imaging, chemical libraries, laboratory automation, and clinical evidence. Generative models are broadening compound-design options, while active-learning systems can help determine which experiments should be performed next. These advances increase the importance of model interpretability, data provenance, standardized formats, and robust prospective validation.

AI can reduce manual prioritization, identify relationships that are difficult to detect through conventional analysis, and improve the allocation of laboratory resources. At the same time, models can reproduce bias, overfit limited datasets, generate chemically or biologically implausible outputs, and create misleading confidence. Effective use therefore requires human review, uncertainty assessment, independent validation, cybersecurity controls, and monitoring across the full discovery lifecycle.

North America benefits from strong biomedical research, advanced cloud infrastructure, and active links between academia, biotechnology, and pharmaceutical development. Europe combines substantial scientific capacity with stringent privacy and medical-data governance, making federated learning, explainability, and compliant data use particularly important. Asia-Pacific is expanding through investments in biotechnology, computing, and translational research, with adoption patterns varying across its diverse economies. Latin America is emphasizing research collaboration, digitization, and access to specialized capabilities. The Middle East is developing innovation ecosystems and data infrastructure, while Africa faces greater constraints in research capacity, connectivity, and interoperable health data, alongside opportunities for locally relevant applications.

ASEAN countries are positioned to benefit from cross-border research and shared technical standards, although differences in regulatory maturity and infrastructure remain significant. BRICS members bring substantial scientific, population, and computational resources but require stronger interoperability and trust mechanisms for multinational collaboration. The European Union emphasizes privacy, risk management, and accountable AI; the G7 focuses on advanced research, responsible governance, and resilience; the GCC is investing in digital infrastructure and innovation capacity; and NATO members increasingly view secure health-data systems, supply-chain resilience, and cyber protection as strategic priorities.

The United States and Canada combine deep life-science expertise with mature digital ecosystems, while the United Kingdom, France, Germany, Italy, and Spain contribute strong academic, clinical, and regulatory capabilities within Europe. Australia is advancing translational research and national data initiatives. China is strengthening computational biology, industrial innovation, and large-scale research infrastructure; Japan emphasizes precision medicine, robotics, and high-quality clinical science; and South Korea is integrating biotechnology with advanced computing. India is expanding bioinformatics, engineering talent, and pharmaceutical research. Brazil and Mexico are building capacity through universities, healthcare digitization, and regional partnerships, while Russia retains substantial scientific expertise but faces constraints linked to international collaboration, technology access, and data connectivity.

Industry leaders should begin with clearly defined scientific and operational problems rather than adopting AI as an end in itself. They should establish governed data foundations, document lineage and model performance, validate outputs prospectively, and connect computational predictions to laboratory and clinical feedback. Cross-functional teams combining medicinal chemistry, biology, clinical science, data engineering, regulatory expertise, and ethics are essential. Partnerships can expand access to specialized datasets and capabilities, but agreements should address privacy, intellectual property, reproducibility, security, and responsibility for decisions.

This executive summary is based on a structured assessment of the artificial-intelligence-in-drug-discovery domain, organized around technology applications, research workflows, enabling infrastructure, governance, regional conditions, and stakeholder groups. Insights were synthesized from established scientific and policy themes, including machine learning, generative chemistry, bioinformatics, clinical data, laboratory automation, validation, privacy, and cybersecurity. The analysis avoids unsupported numerical claims and treats regional, group, and country differences as qualitative patterns requiring continued review as evidence and regulation evolve.

AI is becoming an important layer of modern drug discovery, but its contribution depends on the quality of underlying evidence and the strength of the surrounding operating model. Organizations that combine domain expertise with rigorous validation, secure data practices, interoperable systems, and accountable governance are better positioned to convert computational insight into credible biological and clinical progress. The central opportunity is not simply faster prediction, but more disciplined learning across the discovery process.